The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains.
The presence of lactoferrin at the concentration found in cystic fibrosis (CF) sputum (0.9 g/L) reduced MICs and MBCs of doxycycline for Burkholderia cepacia and Pseudomonas aeruginosa strains. MICs for B. cepacia fell by 32- to 64-fold, from highly resistant to clinically achievable values. Rifampicin MICs for B. cepacia strains were reduced by lactoferrin and for some strains MBCs were reduced. These findings suggest new therapeutic approaches to infections and question the relevance of standard sensitivity tests for CF pathogens. Addition of lactoferrin to media for the routine sensitivity testing of CF isolates might give more relevant results.
Alkawash
M
M
Department of Pathological Sciences, University of Manchester, Manchester Royal Infirmary, UK.
Head
M
M
Alshami
I
I
Soothill
J S
JS
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000904:Antibiotics, Antitubercular / Q000494:pharmacology; D016956:Burkholderia cepacia / Q000187:drug effects*; D003550:Cystic Fibrosis / Q000378:metabolism / Q000382:microbiology; D004318:Doxycycline / Q000494:pharmacology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007781:Lactoferrin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology*; D013183:Sputum / Q000737:chemistry
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D007781:Lactoferrin; D004318:Doxycycline; D012293:Rifampin